Neonatal seizures: controversies and challenges in translating new therapies from the lab to the isolette.
Neonatal seizures have unique properties that have proved challenging for both clinicians and basic science researchers. Clinical therapies aimed at neonatal seizures have proven only partially effective and new therapies are slow to develop. This article will discuss neonatal seizures within the framework of the barriers that exist to the development of new therapies, and the challenges inherent in bringing new therapies from the bench to the bedside. With the European Union and USA creating national collaborative project infrastructure, improved collaborative resources should advance clinical research on urgently needed new therapies for this disorder.
Department of Pediatrics, Section of Pediatric Neurology, University of Colorado School Of Medicine, Children's Hospital Colorado, 13123 East 16th Ave, B155, Aurora, CO 80045, USA.
Kevin E
KE
Chapman
Yogendra H
YH
Raol
Amy
A
Brooks-Kayal
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use; D001921:Brain / Q000254:growth & development* / Q000503:physiopathology; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000191:economics / Q000639:trends; D006801:Humans; D007231:Infant, Newborn; D051379:Mice; D058990:Molecular Targeted Therapy; D051381:Rats; D012640:Seizures / Q000188:drug therapy* / Q000209:etiology
D000927:Anticonvulsants